{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T14:51:12Z","timestamp":1793803872054,"version":"4.6.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"DOI":"10.1038\/s43856-026-01392-1","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T16:07:18Z","timestamp":1769702838000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The clinical significance of the Mediterranean fever gene MEFV variants in Castleman disease"],"prefix":"10.1038","volume":"6","author":[{"given":"Yumo","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangfeng","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqi","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4252-1026","authenticated-orcid":false,"given":"Wenjuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangzhou","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haijiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiping","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxun","family":"Zhuansun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianguo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanping","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danian","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3693-3040","authenticated-orcid":false,"given":"Kezhi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"key":"1392_CR1","first-page":"1","volume":"34","author":"L Zhang","year":"2023","unstructured":"Zhang, L. et al. A national, multicenter, retrospective study of Castleman disease in China implementing CDCN criteria. Lancet Reg. Health West Pac. 34, 1\u201310 (2023).","journal-title":"Lancet Reg. Health West Pac."},{"key":"1392_CR2","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio, R. et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms. Leukemia 36, 1720\u20131748 (2022).","journal-title":"Leukemia"},{"key":"1392_CR3","doi-asserted-by":"publisher","unstructured":"Chen, L. Y. C., Zhang, L. & Fajgenbaum, D. C. Expert perspective: diagnosis and treatment of Castleman disease. Arthritis Rheumatol. (2025). https:\/\/doi.org\/10.1002\/art.43269 Online ahead of print.","DOI":"10.1002\/art.43269"},{"key":"1392_CR4","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1182\/bloodadvances.2024014391","volume":"9","author":"SK Pierson","year":"2025","unstructured":"Pierson, S. K. et al. Characterizing the heterogeneity of Castleman disease and oligocentric subtype: findings from the ACCELERATE registry. Blood Adv. 9, 1952\u20131965 (2025).","journal-title":"Blood Adv."},{"key":"1392_CR5","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s12185-019-02780-1","volume":"111","author":"Y Masaki","year":"2020","unstructured":"Masaki, Y. et al. 2019 Updated diagnostic criteria and disease severity classification for TAFRO syndrome. Int. J. Hematol. 111, 155\u2013158 (2020).","journal-title":"Int. J. Hematol."},{"key":"1392_CR6","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1002\/ajh.26292","volume":"96","author":"Y Nishimura","year":"2021","unstructured":"Nishimura, Y. et al. Validated International Definition of the TAFRO clinical subtype of idiopathic multicentric Castleman disease. Am. J. Hematol. 96, 1241\u20131252 (2021).","journal-title":"Am. J. Hematol."},{"key":"1392_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2431-14-139","volume":"14","author":"I Kubokawa","year":"2014","unstructured":"Kubokawa, I. et al. The first report of adolescent TAFRO syndrome, a unique clinicopathologic variant of multicentric Castleman\u2019s disease. BMC Pediatr. 14, 1\u20138 (2014).","journal-title":"BMC Pediatr."},{"key":"1392_CR8","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/pbc.29261","volume":"68","author":"H Lust","year":"2021","unstructured":"Lust, H., Gong, S., Remiker, A. & Rossoff, J. Idiopathic multicentric Castleman disease with TAFRO clinical subtype responsive to IL-6\/JAK inhibition: a pediatric case series. Pediatr. Blood Cancer 68, 10\u201313 (2021).","journal-title":"Pediatr. Blood Cancer"},{"key":"1392_CR9","doi-asserted-by":"crossref","unstructured":"Mosleh, E. et al. Idiopathic multicentric Castleman disease in an adolescent diagnosed following COVID-19 infection. Pediatr. Blood Cancer 70, e30239 (2023).","DOI":"10.1002\/pbc.30239"},{"key":"1392_CR10","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/pbc.31759","volume":"72","author":"S Palmeri","year":"2025","unstructured":"Palmeri, S. et al. Efficacy of high-dose intravenous anakinra in pediatric TAFRO Syndrome: report of two cases and literature review. Pediatr. Blood Cancer 72, 6\u201311 (2025).","journal-title":"Pediatr. Blood Cancer"},{"key":"1392_CR11","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1182\/blood-2018-05-848671","volume":"132","author":"DC Fajgenbaum","year":"2018","unstructured":"Fajgenbaum, D. C. Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease. Blood 132, 2323\u20132330 (2018).","journal-title":"Blood"},{"key":"1392_CR12","doi-asserted-by":"crossref","unstructured":"Carbone, A. et al. Castleman disease. Nat. Rev. Dis. Primers 7, 84 (2021).","DOI":"10.1038\/s41572-021-00317-7"},{"key":"1392_CR13","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2217\/imt.15.95","volume":"8","author":"DC Fajgenbaum","year":"2016","unstructured":"Fajgenbaum, D. C. & Kurzrock, R. Siltuximab: A targeted therapy for idiopathic multicentric Castleman disease. Immunotherapy 8, 17\u201326 (2016).","journal-title":"Immunotherapy"},{"key":"1392_CR14","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3960\/jslrt.22010","volume":"62","author":"R Sumiyoshi","year":"2022","unstructured":"Sumiyoshi, R., Koga, T. & Kawakami, A. Candidate biomarkers for idiopathic multicentric Castleman disease. J. Clin. Exp. Hematol. 62, 85\u201390 (2022).","journal-title":"J. Clin. Exp. Hematol."},{"key":"1392_CR15","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/rheumatology\/kep121","volume":"48","author":"I Kon\u00e9-Paut","year":"2009","unstructured":"Kon\u00e9-Paut, I. et al. The clinical spectrum of 94 patients carrying a single mutated MEFV allele. Rheumatology 48, 840\u2013842 (2009).","journal-title":"Rheumatology"},{"key":"1392_CR16","doi-asserted-by":"publisher","unstructured":"Borocco, C. et al. The French paediatric cohort of Castleman disease: a retrospective report of 23 patients. Orphanet J Rare Dis. 15, https:\/\/doi.org\/10.1186\/S13023-020-1345-5 (2020).","DOI":"10.1186\/S13023-020-1345-5"},{"key":"1392_CR17","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108547","volume":"219","author":"Y Endo","year":"2020","unstructured":"Endo, Y. et al. Successful canakinumab treatment for activated innate response in idiopathic Castleman\u2019s disease with multiple heterozygous MEFV exon 2 variants. Clin. Immunol. 219, 108547 (2020).","journal-title":"Clin. Immunol."},{"key":"1392_CR18","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/rheumatology\/keaa269","volume":"60","author":"Y Endo","year":"2021","unstructured":"Endo, Y. et al. Idiopathic multicentric Castleman disease with novel heterozygous Ile729Met mutation in exon 10 of familial Mediterranean fever gene. Rheumatology 60, 445\u2013450 (2021).","journal-title":"Rheumatology"},{"key":"1392_CR19","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/cei.13632","volume":"206","author":"Y Endo","year":"2021","unstructured":"Endo, Y. et al. Mediterranean fever gene variants modify clinical phenotypes of idiopathic multi-centric Castleman disease. Clin. Exp. Immunol. 206, 91\u201398 (2021).","journal-title":"Clin. Exp. Immunol."},{"key":"1392_CR20","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41586-022-04625-0","volume":"605","author":"MA Mazid","year":"2022","unstructured":"Mazid, M. A. et al. Rolling back human pluripotent stem cells to an eight-cell embryo-like stage. Nature 605, 315\u2013324 (2022).","journal-title":"Nature"},{"key":"1392_CR21","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: Ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"1392_CR22","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","volume":"177","author":"T Stuart","year":"2019","unstructured":"Stuart, T. et al. Comprehensive integration of single-cell data. Cell 177, 1888\u20131902.e21 (2019).","journal-title":"Cell"},{"key":"1392_CR23","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.cels.2019.03.003","volume":"8","author":"CS McGinnis","year":"2019","unstructured":"McGinnis, C. S., Murrow, L. M. & Gartner, Z. J. DoubletFinder: doublet detection in single-cell RNA sequencing data using artificial nearest neighbors. Cell Syst. 8, 329\u2013337.e4 (2019).","journal-title":"Cell Syst."},{"key":"1392_CR24","doi-asserted-by":"publisher","unstructured":"Zhou, Y. et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat. Commun. 10, https:\/\/doi.org\/10.1038\/s41467-019-09234-6 (2019).","DOI":"10.1038\/s41467-019-09234-6"},{"key":"1392_CR25","first-page":"1","volume":"12","author":"S Jin","year":"2021","unstructured":"Jin, S. et al. Inference and analysis of cell-cell communication using CellChat. Nat. Commun. 12, 1\u201320 (2021).","journal-title":"Nat. Commun."},{"key":"1392_CR26","unstructured":"Chun, F., Junjie, H. & Jiaping, C. Early recognition and optimized management of tafro syndrome: a 10-year experience from a single center in China. In Proc. 67th ASH Annual Meeting abs25\u2013abs1003 (American Society of Hematology, 2025)."},{"key":"1392_CR27","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1182\/blood-2018-07-862334","volume":"132","author":"F Van Rhee","year":"2018","unstructured":"Van Rhee, F. et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood 132, 2115\u20132124 (2018).","journal-title":"Blood"},{"key":"1392_CR28","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1182\/blood-2018-11-884577","volume":"133","author":"L Zhang","year":"2019","unstructured":"Zhang, L. et al. Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease. Blood 133, 1720\u20131728 (2019).","journal-title":"Blood"},{"key":"1392_CR29","unstructured":"Zhang, L., Ge, J. & Li, S. Idiopathic multicentric castleman disease - tafro: a potentially curable disease? In Proc. 67th ASH Annual Meeting abs25\u2013abs1245 (American Society of Hematology, 2025)."},{"key":"1392_CR30","unstructured":"Austin, B., Shyamsundar, S. & Bustamante, M. S. Pediatric iMCD is often severe and responds to siltuximab. In Proc. ASH Annual Meeting Vol. 67, abs25\u20131116 (American Society of Hematology, 2025)."},{"key":"1392_CR31","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/art.10575","volume":"46","author":"C Notarnicola","year":"2002","unstructured":"Notarnicola, C. et al. Reduced MEFV messenger RNA expression in patients with familial Mediterranean fever. Arthritis Rheumatol. 46, 2785\u20132793 (2002).","journal-title":"Arthritis Rheumatol."},{"key":"1392_CR32","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1189\/jlb.1105683","volume":"80","author":"DA Fraser","year":"2006","unstructured":"Fraser, D. A. et al. C1q and MBL, components of the innate immune system, influence monocyte cytokine expression. J. Leukoc. Biol. 80, 107\u2013116 (2006).","journal-title":"J. Leukoc. Biol."},{"key":"1392_CR33","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1501659","author":"S Thanei","year":"2016","unstructured":"Thanei, S. & Trendelenburg, M. Anti-C1q autoantibodies from systemic lupus erythematosus patients induce a proinflammatory phenotype in macrophages. J. Immunol. https:\/\/doi.org\/10.4049\/jimmunol.1501659 (2016).","journal-title":"J. Immunol."},{"key":"1392_CR34","first-page":"1","volume":"16","author":"D Smith","year":"2025","unstructured":"Smith, D. et al. Spatial and single cell mapping of Castleman disease reveals key stromal cell types and cytokine pathways. Nat. Commun. 16, 1\u201314 (2025).","journal-title":"Nat. Commun."},{"key":"1392_CR35","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/art.22320","volume":"56","author":"D \u00dcstek","year":"2007","unstructured":"\u00dcstek, D. et al. Association between reduced levels of MEFV messenger RNA in peripheral blood leukocytes and acute inflammation. Arthritis Rheumatol. 56, 345\u2013350 (2007).","journal-title":"Arthritis Rheumatol."},{"key":"1392_CR36","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1136\/ard.2009.113415","volume":"69","author":"JG Ryan","year":"2010","unstructured":"Ryan, J. G. et al. Clinical features and functional significance of the P369S\/R408Q variant in pyrin, the familial Mediterranean fever protein. Ann. Rheum. Dis. 69, 1383\u20131388 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"1392_CR37","first-page":"2140","volume":"57","author":"D Wu","year":"2018","unstructured":"Wu, D., Shen, M. & Zeng, X. Familial Mediterranean fever in Chinese adult patients. Rheumatology 57, 2140\u20132144 (2018).","journal-title":"Rheumatology"},{"key":"1392_CR38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-014-0439-7","volume":"16","author":"D Kishida","year":"2014","unstructured":"Kishida, D. et al. Genotype-phenotype correlation in Japanese patients with familial Mediterranean fever: differences in genotype and clinical features between Japanese and Mediterranean populations. Arthritis Res. Ther. 16, 1\u201310 (2014).","journal-title":"Arthritis Res. Ther."},{"key":"1392_CR39","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.semarthrit.2019.05.002","volume":"49","author":"Y Hua","year":"2019","unstructured":"Hua, Y. et al. Phenotypes and genotypes of Chinese adult patients with systemic autoinflammatory diseases. Semin. Arthritis Rheum. 49, 446\u2013452 (2019).","journal-title":"Semin. Arthritis Rheum."},{"key":"1392_CR40","doi-asserted-by":"crossref","first-page":"328","DOI":"10.3346\/jkms.2013.28.2.328","volume":"28","author":"K Joo","year":"2013","unstructured":"Joo, K. et al. Extensive thrombosis in a patient with familial mediterranean fever, despite hyperimmunoglobulin D state in serum\u2014first adult case in Korea. J. Korean Med. Sci. 28, 328\u2013330 (2013).","journal-title":"J. Korean Med. Sci."},{"key":"1392_CR41","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1080\/14397595.2017.1267173","volume":"27","author":"K Yamagami","year":"2017","unstructured":"Yamagami, K. et al. Familial Mediterranean fever with P369S\/R408Q exon3 variant in pyrin presenting as symptoms of PFAPA. Mod. Rheumatol. 27, 356\u2013359 (2017).","journal-title":"Mod. Rheumatol."},{"key":"1392_CR42","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1086\/302459","volume":"65","author":"C Cazeneuve","year":"1999","unstructured":"Cazeneuve, C. et al. MEFV-gene analysis in Armenian patients with familial Mediterranean fever: diagnostic value and unfavorable renal prognosis of the M694V homozygous genotype\u2014genetic and therapeutic implications. Am. J. Hum. Genet. 65, 88\u201397 (1999).","journal-title":"Am. J. Hum. Genet."},{"key":"1392_CR43","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1093\/hmg\/7.8.1317","volume":"7","author":"A Bernot","year":"1998","unstructured":"Bernot, A. et al. Non-founder mutations in the MEFV gene establish this gene as the cause of familial Mediterranean fever (FMF). Hum. Mol. Genet. 7, 1317\u20131325 (1998).","journal-title":"Hum. Mol. Genet."},{"key":"1392_CR44","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jaci.2023.07.023","volume":"153","author":"C Bloch","year":"2024","unstructured":"Bloch, C., Jais, P., Gil, M. & Boubaya, M. Severe adult hemophagocytic lymphohistiocytosis (HLHa) correlates with HLH-related gene variants. J. Allergy Clin. Immunol. 153, 256\u2013264 (2024).","journal-title":"J. Allergy Clin. Immunol."},{"key":"1392_CR45","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1136\/annrheumdis-2011-200977","volume":"71","author":"S Federici","year":"2012","unstructured":"Federici, S. et al. Clinical impact of MEFV mutations in children with periodic fever in a prevalent Western European Caucasian population. Ann. Rheum. Dis. 71, 1961\u20131965 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"1392_CR46","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/bjh.19827","volume":"206","author":"YH Gao","year":"2025","unstructured":"Gao, Y. H. et al. Efficacy and safety of orelabrutinib in relapsed\/refractory idiopathic multicentric Castleman disease: a single-centre, retrospective study. Br. J. Haematol. 206, 152\u2013158 (2025).","journal-title":"Br. J. Haematol."},{"key":"1392_CR47","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMc2412494","volume":"392","author":"MD","year":"2025","unstructured":"MD et al. Identifying and targeting TNF signaling in idiopathic multicentric Castleman\u2019s disease. N. Engl. J. Med. 392, 616\u2013618 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1392_CR48","doi-asserted-by":"publisher","unstructured":"Yin, X. et al. IFN-\u03b3 promotes the progression of iMCD by activating inflammatory monocytes. Blood https:\/\/doi.org\/10.1182\/blood.2024027689 (2025).","DOI":"10.1182\/blood.2024027689"},{"key":"1392_CR49","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1038\/s41388-024-03128-8","volume":"43","author":"X Yin","year":"2024","unstructured":"Yin, X. et al. scRNA-seq reveals the landscape of immune repertoire of PBMNCs in iMCD. Oncogene 43, 2795\u20132805 (2024).","journal-title":"Oncogene"},{"key":"1392_CR50","first-page":"1","volume":"5","author":"RAL Pai","year":"2020","unstructured":"Pai, R. A. L. et al. Type i IFN response associated with mTOR activation in the TAFRO subtype of idiopathic multicentric Castleman disease. JCI Insight 5, 1\u201319 (2020).","journal-title":"JCI Insight"},{"key":"1392_CR51","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1182\/blood.2023021992","volume":"143","author":"JY Chan","year":"2024","unstructured":"Chan, J. Y. et al. Single-cell landscape of idiopathic multicentric Castleman disease in identical twins. Blood 143, 1837\u20131844 (2024).","journal-title":"Blood"},{"key":"1392_CR52","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/s41591-021-01329-2","volume":"27","author":"E Stephenson","year":"2021","unstructured":"Stephenson, E. et al. Single-cell multi-omics analysis of the immune response in COVID-19. Nat. Med. 27, 904\u2013916 (2021).","journal-title":"Nat. Med."},{"key":"1392_CR53","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.immuni.2020.11.017","volume":"53","author":"JP Bernardes","year":"2020","unstructured":"Bernardes, J. P. et al. Longitudinal multi-omics analyses identify responses of megakaryocytes, erythroid cells, and plasmablasts as hallmarks of severe COVID-19. Immunity 53, 1296\u20131314.e9 (2020).","journal-title":"Immunity"},{"key":"1392_CR54","first-page":"e64","volume":"188","author":"L You","year":"2020","unstructured":"You, L. et al. Whole-exome sequencing identifies novel somatic alterations associated with outcomes in idiopathic multicentric Castleman disease. Br. J. Haematol. 188, e64\u2013e67 (2020).","journal-title":"Br. J. Haematol."}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01392-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01392-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01392-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T14:57:12Z","timestamp":1771426632000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01392-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1392"],"URL":"https:\/\/doi.org\/10.1038\/s43856-026-01392-1","relation":{},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]},"assertion":[{"value":"13 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"121"}}